Search research articles
Contact Us
Filters
Showing results (651-660 of 721) with videos related to
Page
of 73
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 10, 2024
Impact of <sup>18</sup>F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial
Kai Jannusch, Lale Umutlu, Julian Kirchner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
<sup>68</sup>Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M Pabst, et al.
Neuro-Oncology Advances
|
January 7, 2026
Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?
Christoph Oster, Pia Reineck, Teresa Schmidt, et al.
Cancer Treatment Reviews
|
July 9, 2021
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, et al.
Theranostics
|
September 23, 2024
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of <sup>68</sup>Ga-SSO120 PET with immunohistochemistry and survival
Ilektra Antonia Mavroeidi, Anna Romanowicz, Tristan Haake, et al.
The Lancet. Oncology
|
August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 22, 2022
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on <sup>18</sup>F-FDG PET/MRI and Machine Learning
Janna Morawitz, Benjamin Sigl, Christian Rubbert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
Page
of 73
Search research articles
Search
Showing results (651-660 of 721) with videos related to
Sort By:
Page
of 73
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
October 10, 2024
Impact of <sup>18</sup>F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial
Kai Jannusch, Lale Umutlu, Julian Kirchner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 25, 2023
<sup>68</sup>Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
Riccardo Mei, Lukas Kessler, Kim M Pabst, et al.
Neuro-Oncology Advances
|
January 7, 2026
Distribution and prognostic significance of myelotoxicity in newly diagnosed glioblastoma in a real-life cohort: Time to treat more aggressively?
Christoph Oster, Pia Reineck, Teresa Schmidt, et al.
Cancer Treatment Reviews
|
July 9, 2021
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer
Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, et al.
Theranostics
|
September 23, 2024
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of <sup>68</sup>Ga-SSO120 PET with immunohistochemistry and survival
Ilektra Antonia Mavroeidi, Anna Romanowicz, Tristan Haake, et al.
The Lancet. Oncology
|
August 1, 2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J Karpinski, Johannes Hüsing, Kevin Claassen, et al.
European Urology
|
March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study
Manuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
The Lancet. Oncology
|
June 3, 2023
Health-related quality of life and pain outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Karim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 22, 2022
Clinical Decision Support for Axillary Lymph Node Staging in Newly Diagnosed Breast Cancer Patients Based on <sup>18</sup>F-FDG PET/MRI and Machine Learning
Janna Morawitz, Benjamin Sigl, Christian Rubbert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 15, 2017
<sup>68</sup>Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, et al.
Page
of 73